ResearcherActive in the last 2 years

L.-Z. Liu

ORCID-verified (high confidence)As of 9 November 2026

Matched on ORCID iD 0000-0001-9234-457X; OpenAlex author ID A5100349504.

Their work

Papers: 3 (first author 0, last author 1)
Trials: 0
Grants: 0
Collaborators: 6

Papers, trials and grants by year

2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 3

Prognostic Model Construction of Disulfidptosis-Related Genes and Targeted Anticancer Drug Research in Pancreatic Cancer. Co-author DOI 10.1007/s12033-024-01131-8 ↗
Somatostatin Inhibited the EMT of Pancreatic Cancer Cells by Mediating the TGF-β/Smad Signaling Pathway. Last author DOI 10.24976/discov.med.202335179.105 ↗
MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells. Co-author DOI 10.18632/oncotarget.12268 ↗

Closest collaborators

The 6 strongest of 6 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

Wenting Wang · 1 shared paper, 2023
- Paper Somatostatin Inhibited the EMT of Pancreatic Cancer Cells by Mediating the TGF-β/Smad Signaling Pathway. DOI 10.24976/discov.med.202335179.105 ↗
Xuan Zhou · 1 shared paper, 2023
- Paper Somatostatin Inhibited the EMT of Pancreatic Cancer Cells by Mediating the TGF-β/Smad Signaling Pathway. DOI 10.24976/discov.med.202335179.105 ↗
Yan Shen · 1 shared paper, 2025
- Paper Prognostic Model Construction of Disulfidptosis-Related Genes and Targeted Anticancer Drug Research in Pancreatic Cance… DOI 10.1007/s12033-024-01131-8 ↗
Hongtao Duan · 1 shared paper, 2025
- Paper Prognostic Model Construction of Disulfidptosis-Related Genes and Targeted Anticancer Drug Research in Pancreatic Cance… DOI 10.1007/s12033-024-01131-8 ↗
Yuan Lu · 1 shared paper, 2016
- Paper MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells. DOI 10.18632/oncotarget.12268 ↗
Yong Lin · 1 shared paper, 2016
- Paper MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells. DOI 10.18632/oncotarget.12268 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.